Findings

What do systematic reviews say?

521 questions · 544 findings · 62 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 153 · 28.1%GRADE not reported 29 · 5.3%Very low 134 · 24.6%Low 123 · 22.6%Moderate 80 · 14.7%High 25 · 4.6%

Viaskin milk patch vs placebo

Clinical improvement (dichotomous) · active EoE pediatric patients

The review found no eligible studies for this question.

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Viaskin milk patch vs placebo

Clinical improvement (continuous) · active EoE pediatric patients

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 9 participants
Low

Viaskin milk patch vs placebo

Histological improvement (dichotomous) · active EoE pediatric patients

The review found no eligible studies for this question.

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Viaskin milk patch vs placebo

Histological improvement (continuous) · active EoE pediatric patients

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 9 participants
Low

Viaskin milk patch vs placebo

Endoscopic improvement (dichotomous) · active EoE pediatric patients

The review found no eligible studies for this question.

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Viaskin milk patch vs placebo

Endoscopic improvement (continuous) · active EoE pediatric patients

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 20 participants
Low

Viaskin milk patch vs placebo

Withdrawals due to adverse events · active EoE pediatric patients

Viaskin milk patch showed no clear difference in withdrawals due to adverse events at 44 weeks compared with placebo (low certainty).

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
RR 1.12 [0.05, 23.99]
1 study · 20 participants
Low

Leukotriene receptor antagonist vs placebo

Clinical improvement (dichotomous) · inactive EoE patients

It is very uncertain whether leukotriene receptor antagonist changes clinical improvement at 26 weeks (dichotomous) compared with placebo (very low certainty).

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
RR 1.68 [0.66, 4.28]
1 study · 41 participants
Very low

Aspirin vs placebo

Graft thrombosis (up to 18 months) · people with ESRD receiving haemodialysis through an arteriovenous fistula or graft

Aspirin showed no clear difference in graft thrombosis (28 days to 18 months) compared with placebo (low certainty).

1 finding from 1 review

Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts 2021 · Cochrane Headline outcomes only
OR 0.4 [0.07, 2.25]
3 studies · 175 participants
Low

Dipyridamole vs placebo

Length of hospital stay · people with ESRD receiving haemodialysis through an arteriovenous graft

The review found no eligible studies for this question.

1 finding from 1 review

Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Dipyridamole vs placebo

Complications (up to 18 months) · people with ESRD receiving haemodialysis through an arteriovenous graft

1 finding from 1 review

Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 42 participants
Low

Dipyridamole vs placebo

Number of related surgical or radiological interventions · people with ESRD receiving haemodialysis through an arteriovenous graft

The review found no eligible studies for this question.

1 finding from 1 review

Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Dipyridamole plus aspirin vs placebo

Graft thrombosis (up to 18 months) · people with ESRD receiving haemodialysis through an arteriovenous graft

Dipyridamole plus aspirin showed no clear difference in graft thrombosis (up to 18 months) compared with placebo (moderate certainty).

1 finding from 1 review

Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts 2021 · Cochrane Headline outcomes only
OR 0.64 [0.16, 2.56]
1 study · 41 participants
Moderate

Dipyridamole plus aspirin vs placebo

Length of hospital stay · people with ESRD receiving haemodialysis through an arteriovenous graft

The review found no eligible studies for this question.

1 finding from 1 review

Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Dipyridamole plus aspirin vs placebo

Complications (up to 18 months) · people with ESRD receiving haemodialysis through an arteriovenous graft

1 finding from 1 review

Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 41 participants
Low

Dipyridamole plus aspirin vs placebo

Number of related surgical or radiological interventions · people with ESRD receiving haemodialysis through an arteriovenous graft

The review found no eligible studies for this question.

1 finding from 1 review

Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Warfarin vs placebo

Graft thrombosis (up to 3 months) · people with ESRD receiving haemodialysis through an arteriovenous graft

Warfarin showed no clear difference in graft thrombosis (up to 37 months) compared with placebo (low certainty).

1 finding from 1 review

Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts 2021 · Cochrane Headline outcomes only
OR 1.76 [0.78, 3.99]
1 study · 107 participants
Low

Warfarin vs placebo

Length of hospital stay · people with ESRD receiving haemodialysis through an arteriovenous graft

The review found no eligible studies for this question.

1 finding from 1 review

Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Warfarin vs placebo

Complications (up to 37 months) · people with ESRD receiving haemodialysis through an arteriovenous graft

1 finding from 1 review

Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 107 participants
Low

Aspirin vs placebo

Length of hospital stay · people with ESRD receiving haemodialysis through an arteriovenous fistula or graft

The review found no eligible studies for this question.

1 finding from 1 review

Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found